Role of VASP Phosphorylation Assay in Monitoring the Antiplatelet Therapy

Abstract

Dual antiplatelet treatment with clopidogrel and aspirin represents standard regimen in prevention of thromboembolic events in patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI). One of the greatest pitfalls of clopidogrel treatment is large inter-individual variability in response. Large amount of patients does not respond adequately and therefore are not „protected“ even in spite of receiving the therapy. Poor responders are exposed to three-fold increased risk of myocardial infarction, stent thrombosis and cardiac death.

Keywords

• acute coronary syndrome
• clopidogrel
• flow cytometry
• platelet reactivity
• vasodilator stimulated phosphoprotein (vasp)